[1] |
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
doi: 10.3322/caac.v72.1
|
[2] |
XIA C F, DONG X S, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
|
[3] |
SLAMON D J, LEYLAND-JONES B, SHAK S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-792.
doi: 10.1056/NEJM200103153441101
|
[4] |
WU J, JIANG Z F, LIU Z Z, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial[J]. BMC Med, 2022, 20(1): 498.
doi: 10.1186/s12916-022-02708-3
pmid: 36575513
|
[5] |
XU B H, YAN M, MA F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2021, 22(3): 351-360.
doi: 10.1016/S1470-2045(20)30702-6
pmid: 33581774
|
[6] |
HUA X, BI X W, ZHAO J L, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002)[J]. Clin Cancer Res, 2022, 28(4): 637-645.
doi: 10.1158/1078-0432.CCR-21-3435
|
[7] |
YAN M, OUYANG Q, SUN T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial[J]. Lancet Oncol, 2022, 23(3): 353-361.
doi: 10.1016/S1470-2045(21)00716-6
pmid: 35085506
|
[8] |
WOLFF A C, HAMMOND M E H, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122.
doi: 10.1200/JCO.2018.77.8738
pmid: 29846122
|
[9] |
TARANTINO P, HAMILTON E, TOLANEY S M, et al. HER2-low breast cancer: pathological and clinical landscape[J]. J Clin Oncol, 2020, 38(17): 1951-1962.
doi: 10.1200/JCO.19.02488
pmid: 32330069
|
[10] |
SLAMON D J, GODOLPHIN W, JONES L A, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244(4905): 707-712.
doi: 10.1126/science.2470152
|
[11] |
SCHNEEWEISS A, PARK-SIMON T W, ALBANELL J, et al. Phase Ⅰb study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer[J]. Invest New Drugs, 2018, 36(5): 848-859.
doi: 10.1007/s10637-018-0562-4
|
[12] |
RINNERTHALER G, GAMPENRIEDER S P, GREIL R. HER2 directed antibody-drug-conjugates beyond T-DM1 in breast cancer[J]. Int J Mol Sci, 2019, 20(5): 1115.
doi: 10.3390/ijms20051115
|
[13] |
MITTENDORF E A, LU B, MELISKO M, et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase Ⅲ clinical trial[J]. Clin Cancer Res, 2019, 25(14): 4248-4254.
doi: 10.1158/1078-0432.CCR-18-2867
|
[14] |
PONDÉ N, AFTIMOS P, PICCART M. Antibody-drug conjugates in breast cancer: a comprehensive review[J]. Curr Treat Options Oncol, 2019, 20(5): 1-22.
|
[15] |
SCHALPER K A, KUMAR S, HUI P, et al. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria[J]. Arch Pathol Lab Med, 2014, 138(2): 213-219.
doi: 10.5858/arpa.2012-0617-OA
|
[16] |
MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
doi: 10.1056/NEJMoa2203690
|
[17] |
DIÉRAS V, DELUCHE E, LUSQUE A, et al. Abstract PD8-02: trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase Ⅱ study with biomarkers analysis (DAISY)[J]. Cancer Res, 2022, 82(4_Supplement): PD8-2.
|
[18] |
CHEN Z H, OUYANG Q C, WANG Y S, et al. Real-world first-line treatment patterns and outcomes in hormone receptor-positive advanced breast cancer patients: a multicenter, retrospective study in China[J]. Front Oncol, 2022, 12: 829693.
doi: 10.3389/fonc.2022.829693
|
[19] |
HARBECK N, RASTOGI P, MARTIN M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study[J]. Ann Oncol, 2021, 32(12): 1571-1581.
doi: 10.1016/j.annonc.2021.09.015
pmid: 34656740
|
[20] |
BAEK S Y, NOH W C, AHN S H, et al. Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial[J]. J Clin Oncol, 2022, 40(16_suppl): 506.
|
[21] |
XU B H, ZHANG Q Y, ZHANG P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial[J]. Nat Med, 2021, 27(11): 1904-1909.
doi: 10.1038/s41591-021-01562-9
pmid: 34737452
|
[22] |
XU B H, ZHANG Q Y, ZHANG P, et al. Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase Ⅲ trial[J]. Ann Oncol, 2022, 33(suppl_7): S808-S869.
|
[23] |
HORTOBAGYI G N, STEMMER S M, BURRIS H A, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer[J]. N Engl J Med, 2022, 386(10): 942-950.
doi: 10.1056/NEJMoa2114663
|
[24] |
LU Y S, IM S A, COLLEONI M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase Ⅲ randomized clinical trial[J]. Clin Cancer Res, 2022, 28(5): 851-859.
doi: 10.1158/1078-0432.CCR-21-3032
|
[25] |
SLAMON D J, NEVEN P, CHIA S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase Ⅲ randomized MONALEESA-3 trial: updated overall survival[J]. Ann Oncol, 2021, 32(8): 1015-1024.
doi: 10.1016/j.annonc.2021.05.353
|
[26] |
LU Y S, MALWINDER S S, AZIM H, et al. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/ perimenopausal patients with HR+, HER2- inoperable locally advanced breast cancer (ABC): RIGHT choice study[J]. Ann Oncol, 2019, 30: Ⅸ11-Ⅸ12.
|
[27] |
XU B H, HU X C, LI W, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from PALOMA-4[J]. Eur J Cancer, 2022, 175: 236-245.
doi: 10.1016/j.ejca.2022.08.012
pmid: 36155117
|
[28] |
ZHANG L X, WANG H B, YANG J, et al. Clinical outcomes and clinical/genetic risk factors of palbociclib plus endocrine therapy (ET) for HR+ HER2- advanced breast cancer (ABC) patients in Chinese multicenter study of real-world practices[J]. J Clin Oncol, 2022, 40(16_suppl): e13039.
doi: 10.1200/JCO.2022.40.16_suppl.e13039
|
[29] |
BIANCHINI G, BALKO J M, MAYER I A, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease[J]. Nat Rev Clin Oncol, 2016, 13(11): 674-690.
doi: 10.1038/nrclinonc.2016.66
pmid: 27184417
|
[30] |
BARECHE Y, VENET D, IGNATIADIS M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis[J]. Ann Oncol, 2018, 29(4): 895-902.
doi: S0923-7534(19)45470-7
pmid: 29365031
|
[31] |
CORTES J, CESCON D W, RUGO H S, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828.
doi: 10.1016/S0140-6736(20)32531-9
pmid: 33278935
|
[32] |
XIE Y, GONG C, ZHANG J, et al. Phase Ⅱ trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases[J]. BMC Cancer, 2021, 21(1): 1174.
doi: 10.1186/s12885-021-08921-2
|
[33] |
LI D D, TAO Z H, WANG B Y, et al. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial[J]. NPJ Breast Cancer, 2022, 8(1): 110.
doi: 10.1038/s41523-022-00462-6
|
[34] |
WU S Y, XU Y, CHEN L, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial[J]. Mol Cancer, 2022, 21(1): 84.
doi: 10.1186/s12943-022-01536-6
|
[35] |
LIU J Q, WANG Y, TIAN Z L, et al. Multicenter phase Ⅱ trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer[J]. Nat Commun, 2022, 13: 3011.
doi: 10.1038/s41467-022-30569-0
|
[36] |
ZHANG Q Y, SHAO B, TONG Z S, et al. A phase Ⅰb study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer[J]. BMC Med, 2022, 20(1): 321.
doi: 10.1186/s12916-022-02527-6
|